NTRK1 and breast carcinoma: In breast cancers with amplification of the ErbB2 oncogene, which occurs in nearly 30% of breast cancer cases, receptor tyrosine kinase (RTK) inhibitors targeting epidermal growth factor receptors (EGFRs), like trastuzumab and lapatinib, have demonstrated significant clinical benefits as well3, 4.